pf-03049423
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2009 (NCT01161069)
Timeline
Indications
Mechanism of action
- Phosphodiesterase 5AINHIBITOR
PDE5A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCCOCCn1c(=O)c(N2CCN(CCO)CC2)nc2cnc(-c3ccc(OC)nc3)cc21- Mol. weight
- 468.56 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL591501 ↗
Also known as
- 3-(4-(2-hydroxyethyl)piperazin-1-yl)-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido(3,4-b)pyrazin-2(1h)-one
- hmppp-one
- pf-03049423
- pf-03049423
- pf-03049423
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01208233 | Phase 2 | Dec 1, 2010 | Pfizer |
| NCT01161069 | Phase 1 | Aug 1, 2009 | Pfizer |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 2 | 2 | 2 | 2009 |
1 organizations
Page 1 / 1